Navigation Links
NeurogesX Reports Second Quarter 2008 Results
Date:8/13/2008

Second Quarter 2008 Corporate Highlights: - European marketing application under review for NGX-4010 in peripheral

neuropathic pain - NGX-4010 NDA for PHN on track for submission in second half of 2008

- IND submitted and opened for NGX-1998 liquid capsaicin formulation

- Phase 1 clinical trial of NGX-1998 initiated - Journal Neurology published positive Phase 3 data on NGX-4010 in HIV-DSP

SAN MATEO, Calif., Aug. 13 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the quarter ended June 30, 2008.

In the second quarter of 2008, the Company continued on its path toward potential commercialization of its lead product candidate, NGX-4010, a dermal capsaicin patch designed for the treatment of certain neuropathic pain conditions. On the U.S. regulatory front, the Company has been preparing a New Drug Application (NDA) to support marketing approval of NGX-4010 for the treatment of post-herpetic neuralgia (PHN), and is on track to submit an NDA to the U.S. Food and Drug Administration (FDA) later this year.

The Company continues to pursue the European approval of its Marketing Authorization Application (MAA) for NGX-4010 in neuropathic pain, which the European Medicines Agency (EMEA) accepted for review in September 2007. In September of 2008, the Company, with the EMEA's agreement, plans to submit responses to the regulatory agency's Day 120 questions, which are part of the review process for the MAA.

In addition to focusing on regulatory activities for NGX-4010, NeurogesX has made significant progress with
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NeurogesX to Report Second Quarter 2008 Financial Results
2. NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998
3. NeurogesX to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
4. NeurogesX Reports First Quarter 2008 Results
5. NeurogesX to Report First Quarter 2008 Financial Results
6. NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
7. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
8. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX Closes $25 Million Private Placement
11. NeurogesX, Inc. Announces $25 Million Private Placement

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... Dec. 2 Peregrine Pharma...mpletion of patient enrollment in a dose confirmat...s with relapsed glioblastoma multiforme (GBM), the...eted monoclonal antibody linked to a radioisotope ...BM. Cotara specifically targets cells at the cent...
(Date:12/2/2009)...EM, Israel, December 2 Gamida Cell...e preclinical (animal study) safety and,efficacy o... from Weill,Cornell Medical College and Gamida Cel...ed anemias such as Cooley,s Anemia. , Gam... expand, ex vivo,populations of stem/progenitor c...
(Date:12/2/2009)...ec. 2 /PRNewswire-Asia/ -- The world is going thro...d uncertainty is part of many,businesses and indus...een,relatively immune to the economic downturn, be...During the midst of the difficult times this year,...augurated an R&D center in Shanghai, the large...
(Date:12/1/2009)...c. 1 Reportlinker.com announces th...s catalogue: ,, Chromium - Global Market Tren...hromium---Global-Market-Trends.html ,, Worldwi...stainless steel, while growth in aerospace and ind...growth of chromium metal. Environmental constraint...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9
...., Oct. 5 Bionovo, Inc.,(Nasdaq: BNVI ), a leade...ective drugs in the areas of women,s health and ca... CFO of Bionovo, Inc., will present at the 4th,Ann...e place on October 11, 2007 at 12:30 p.m. PDT,at t...o web cast and slide presentation of the event wil...
...CO, Calif., Oct. 5 Cerimon,Pharmaceuticals, Inc.,...and,Chief Executive Officer, will present at the 2...07, at 9:30 a.m. PDT at the Palace Hotel in San,Fr...acific Heights room. About Cerimon Pharmaceutical...tical company dedicated,to developing and commerci...
...5 The Coalition for a,Competitive Pharmaceutical ... on the Food and Drug Administration,s announcemen...Efficiency" (GIVE): "With consumers, employers, i...nage escalating prescription drug costs, it is cri...ays to enhance timely generic access.,Today,s anno...
Other Biology Technology:CCPM Issues Statement on FDA's GIVE Initiative 2
(Date:12/3/2009)...ds the world when it comes to investment in energy...and Physical Sciences Research Council (EPSRC) Chi...ed: "Scientific and engineering research has alrea...ower solutions, but more investment is needed to d...we are to meet our carbon emission targets by 2020...
(Date:12/2/2009)...PHIA Children exposed to secondhand cigarette smo...r in adulthood, even if they never smoked. , Re...miology, Biomarkers & Prevention , a journal of th...t of a special tobacco focus in the December issue...s will be diagnosed with lung cancer; more than 15...
(Date:12/2/2009)...PHIA Cigarette smoking and alcohol consumption be...cts the patient,s future risk of death, according ...show a similar effect among those who continued th...r survivors are counseled to quit smoking; despite...continued to smoke even after their cancer diagnos...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Syngenta Issues EUR 500 Million Eurobond 12745 1Syngenta Issues EUR 500 Million Eurobond 12745 2Physician Receives Bachelors Degree After 50 Years 49750 1Physician Receives Bachelors Degree After 50 Years 49750 2Helix Biopharma Corp Begins Trading on the OTCQX International Market Listing as HXBPF 49749 1Helix Biopharma Corp Begins Trading on the OTCQX International Market Listing as HXBPF 49749 2Helix Biopharma Corp Begins Trading on the OTCQX International Market Listing as HXBPF 49749 3Helix Biopharma Corp Begins Trading on the OTCQX International Market Listing as HXBPF 49749 4
...ls Network, an initiative designed to address the ...tegration of imaging biomarkers into multi-center ... a supporter. , SNM, the world,s largest medical ...ssionals, inaugurated the Clinical Trials Network ...g development through the integration and standard...
...al of a tissue sample is now the standard for diag... are accurate but only offer a snapshot of the tum...or for weeks or months after the biopsy, tracking ... be much more valuable, says Michael Cima, MIT pro...as developed the first implantable device that can...
...erican Society of Civil Engineers (ASCE) has prese...ng, Stabile Professor for Innovation and Technolog... as an expert, contact Sheryl Weinstein at 973-596...f civil and environmental engineering, has 35 year...ivil engineering in both the academic field and pr...
Other Biology News:SNM's clinical trials network gains added support from industry leader 2MIT’s implantable device offers continuous cancer monitoring 2Civil engineers name NJIT's John Schuring Educator of Year Award 2
...ified Formulation: 50mM Tris-HCl, pH 7.5, 0.1mM EG...1% 2-mercaptoethanol and 50% glycerol. Properites:...d enzyme Purification: DEAE-Sephadex, ammonium sul..., Superdex 200, and Mono Q chromatography to >95%....
Beacon 2000 One-Step FP Std from Invitrogen
Beacon 2000 Chamber (6mm, Minimum Vol - 100 uL) from Invitrogen
EvoQuest Custom Peptide Services from Invitrogen
Biology Products: